drugset / Trial / NCT03763422

Trial in Low Grade Glioma Patients: Wait or Treat

NCT03763422

RandomizedParallel-groupOpen-labelTreatment

Summary

The 1635-EORTC-BTG study - Wait or Treat - concerns patients that represent a clinically favorable group of patients with IDHmutated astrocytoma (oligo-symptomatic), without a need for immediate post-operative treatment. It will establish whether early adjuvant treatment with radiotherapy and adjuvant temozolomide in resected IDHmutated astrocytoma will improve outcome, and whether benefits of early treatment outweigh potential side-effects of that, such as deterioration in neurocognitive function or Quality of Live, seizure activity and Patient Reported outcome compared to active surveillance.

Timeline

Start
2020-03-16
Primary completion
2021-12-29
Completion
2021-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule Oral

Indications